207 related articles for article (PubMed ID: 7811398)
1. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
2. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
3. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
4. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
Schuchter LM; Hensley ML; Meropol NJ; Winer EP;
J Clin Oncol; 2002 Jun; 20(12):2895-903. PubMed ID: 12065567
[No Abstract] [Full Text] [Related]
5. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
6. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Sastry J; Kellie SJ
Pediatr Hematol Oncol; 2005; 22(5):441-5. PubMed ID: 16020136
[TBL] [Abstract][Full Text] [Related]
7. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.
Hensley ML; Hagerty KL; Kewalramani T; Green DM; Meropol NJ; Wasserman TH; Cohen GI; Emami B; Gradishar WJ; Mitchell RB; Thigpen JT; Trotti A; von Hoff D; Schuchter LM
J Clin Oncol; 2009 Jan; 27(1):127-45. PubMed ID: 19018081
[TBL] [Abstract][Full Text] [Related]
8. Chemoprotectants for cancer chemotherapy.
Dorr RT
Semin Oncol; 1991 Feb; 18(1 Suppl 2):48-58. PubMed ID: 1899489
[TBL] [Abstract][Full Text] [Related]
9. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
10. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
11. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
12. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Wiseman LR; Spencer CM
Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
[TBL] [Abstract][Full Text] [Related]
13. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
14. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
[TBL] [Abstract][Full Text] [Related]
15. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
16. Current role of chemotherapy protectors in cancer treatment.
Cáceres W; Báez L; Aponte I; Rodríguez N; Maldonado A
Bol Asoc Med P R; 1997; 89(10-12):184-8. PubMed ID: 9577052
[TBL] [Abstract][Full Text] [Related]
17. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
18. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
19. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
20. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity (Review).
Orditura M; De Vita F; Roscigno A; Infusino S; Auriemma A; Iodice P; Ciaramella F; Abbate G; Catalano G
Oncol Rep; 1999; 6(6):1357-62. PubMed ID: 10523712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
